Skip to main content

Progyny, Inc. to Present at BofA Securities 2026 Health Care Conference

NEW YORK, May 11, 2026 (GLOBE NEWSWIRE) — Progyny, Inc. (Nasdaq: PGNY), a global leader in women’s health and family building solutions, today announced that Progyny’s Chief Executive Officer, Pete Anevski, and Chief Financial Officer, Mark Livingston, will participate in a fireside chat at the BofA Securities 2026 Health Care Conference on Tuesday, May 12, 2026, at 11:20 A.M. Pacific Time / 2:20 P.M. Eastern Time. A live audiocast and replay will be available from the Events and Presentations section of Progyny’s website at http://investors.progyny.com. About Progyny Progyny (Nasdaq: PGNY) is a global leader in women’s health and family building solutions, trusted by the nation’s leading employers, health plans and benefit purchasers. We envision a world where everyone can realize their dreams of family and ideal health. Our outcomes...

Continue reading

MIND CTI Reports First Quarter 2026 Results

YOQNEAM, Israel, May 11, 2026 (GLOBE NEWSWIRE) — MIND C.T.I. LTD. – (NasdaqGM: MNDO), a leading provider of convergent end-to-end prepaid/postpaid billing and customer care product based solutions for service providers, unified communications (UC) analytics for enterprises as well as enterprise messaging solutions, today announced results for its first quarter ended March 31, 2026. The following will summarize our major achievements in the first quarter of 2026, as well as our business. The financial results can be found in the Company News section of our website at http://www.mindcti.com/company/news/ and in our Form 6-K. Financial HighlightsRevenues were $5.1 million, compared with $5.0 million in the first quarter of 2025. Operating income was $0.9 million, or 18% of total revenues, compared with $0.4 million, or 7% of total...

Continue reading

Richardson Electronics to Present at the 16th Annual LD Micro Invitational on May 18, 2026

LAFOX, Ill., May 11, 2026 (GLOBE NEWSWIRE) — Richardson Electronics, Ltd. (NASDAQ: RELL), a global provider of engineered solutions for the alternative energy and power management markets, and custom displays for medical and industrial OEMs, today announced that it will be participating in the 16th Annual LD Micro Invitational at the Luxe Sunset Boulevard Hotel in Los Angeles, CA on May 18 – 19, 2026. Richardson Electronics is scheduled to present on Monday, May 18, 2026, at 9:30 AM PT. Edward Richardson, Chairman and CEO and Wendy Diddell COO will be presenting on behalf of the Company. To access the live presentation, please use the following information: LD Micro Invitational XVIDate: Monday, May 18, 2026Time: 9:30 AM-9:55 AM PTWebcast: https://ldmicroevents.com/ If you would like more information about the event or to book 1×1...

Continue reading

Lemonade Launches Award-Winning Renters Insurance in Delaware

Tech-First Insurance Company Expands Its Digital Coverage to Delaware Renters New York City, NY, May 11, 2026 (GLOBE NEWSWIRE) — Lemonade (NYSE: LMND), the tech-first insurance company, has announced the launch of its award-winning renters insurance product in Delaware. This expansion brings Lemonade’s innovative, digital coverage to renters across the state, further solidifying the company’s presence in the United States. Lemonade Renters is crafted to protect the belongings renters value most while offering an unparalleled customer experience. Policies are available from $5 per month and designed with flexibility in mind, allowing customers to choose coverage amounts and deductibles that align with their lifestyle and budget. According to industry and Lemonade data, Lemonade Renters is approximately 30 percent more affordable...

Continue reading

Cytokinetics Announces New Data Related to MYQORZO® (aficamten) at ESC Heart Failure 2026

Multinational Real-world Data Reinforce Favorable Clinical Profile and Long-Term Safety SOUTH SAN FRANCISCO, Calif., May 11, 2026 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the presentation of new data reinforcing the clinical profile of MYQORZO® (aficamten) at the European Society of Cardiology (ESC) Heart Failure 2026 Congress. The presentations include new analyses from SEQUOIA-HCM, the pivotal Phase 3 clinical trial of aficamten in patients with oHCM; MAPLE-HCM, the Phase 3 clinical trial of aficamten compared to metoprolol in patients with symptomatic obstructive HCM (oHCM); and FOREST-HCM, the open-label extension trial of aficamten. Collectively, the new evidence expands understanding of the effectiveness of cardiac myosin inhibition with aficamten compared directly to metoprolol,...

Continue reading

AmpliTech Group To Report First Quarter 2026 Results and Schedules Conference Call

HAUPPAUGE, N.Y., May 11, 2026 (GLOBE NEWSWIRE) — AmpliTech Group, Inc. (NASDAQ: AMPG, AMPGR, AMPGZ) today announced that it will release its financial results for the first quarter ended March 31, 2026, on Wednesday, May 13, 2026, after the market close. The Company will host a conference call the same day at 5:00 p.m. Eastern Time to discuss the results. Investor Earnings Call DetailsDate/Time: Wednesday, May 13th, 2026, at 5:00 PM ETDial-in Number: 1-833-630-0019 (domestic) or 1-412-317-1807 (international)Online Replay: Audio file and call transcript will be posted to AmpliTech’s news page when available.Investor questions may be submitted to investors@amplitechgroup.com prior to the call About AmpliTech Group, Inc. AmpliTech Group, Inc. (NASDAQ: AMPG, AMPGW) designs, develops, and manufactures advanced RF and microwave...

Continue reading

CONVENING NOTICE TO THE EXTRAORDINARY GENERAL MEETING 2026 OF IBA SA

CONVENING NOTICE TO THE EXTRAORDINARY GENERAL MEETING 2026 OF IBA SA – WEDNESDAY JUNE 10, 2026, AT 11:00 A.M. – Dear Shareholder, We have the honor of convening you to the Extraordinary General Meeting (the “EGM“) of IBA to be held on Wednesday June 10, 2026 at 11:00 A.M., to deliberate on the attached agenda. The EGM will be held in person at the Company’s headquarters. There will also be an online webcast, accessible upon prior registration, but it will not be possible to vote online. This is a simple webcast. Shareholders are strongly encouraged to vote in advance of the EGM, within the legal deadlines, by proxy or via the remote voting form (both of which are provided herewith), in order to facilitate the counting of votes. Alternatively, shareholders are offered the possibility of voting via the platform http://www.abnamro.com/evoting...

Continue reading

Airship AI Reports First Quarter 2026 Financial Results

First Quarter 2026 Net Revenues of $6.3 Million, Gross Profit of $3.2 Million and Gross Margin of 50% Net Revenue Increase of 15% and Gross Margin Increase of 42% as Compared to Q1 of the Prior Year REDMOND, Wash., May 11, 2026 (GLOBE NEWSWIRE) — Airship AI Holdings, Inc. (NASDAQ: AISP) (“Airship AI” or the “Company”), a leader in AI-driven video, sensor, and data management surveillance solutions, today reported its financial and operational results for the first quarter ended March 31, 2026. Q1 2026 Financial HighlightsNet revenues for the quarter ended March 31, 2026, were $6.3 million.Gross profits for the quarter ended March 31, 2026, were $3.2 million.Gross margin percentage was 50% for the quarter ended March 31, 2026. Higher margins were in part due to increased solution sales with more Airship AI branded hardware...

Continue reading

Biodesix Announces ATS 2026 Presentations Providing Real-World Clinical Evidence and Healthcare System Economic Value for Nodify Lung® Testing Strategy

Includes real-world clinical data from Biodesix researchers and independent Healthcare Professionals LOUISVILLE, Colo., May 11, 2026 (GLOBE NEWSWIRE) — Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostics solutions company, today announced that additional real-world clinical and economic data related to Nodify Lung® testing will be shared at the American Thoracic Society (ATS) Annual Meeting, May 15 – 20, 2026 | Orlando, FL. The presentations further reinforce the accelerating adoption of Biodesix blood-based testing for earlier detection of lung cancer. “The presentations at ATS highlight the real-world clinical value and economic advantages of lung nodule management programs that use Nodify Lung® testing for risk stratification,” said Scott Hutton, CEO of Biodesix. “It is encouraging to see major academic medical centers and community...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.